Sequential salvage systemic therapy after immunotherapy in head and neck cancer: a real-world study
Cetuximab-based SCAI post-ICI showed high rates of response, which were durable and profound, and improved survival compared to historical data, with modest efficacy in re-sequenced patients. Time on cetuximab was significantly longer than on ICI. These results should be confirmed in a larger prospective study.
Authors
- Salomé Merino-Menéndez
- Santiago Cabezas-Camarero
- M. A. P. Sotelo
- Pablo Pérez-Alonso
- María Nieves Cabrera-Martín
Institutions
- Villa Maria Hospital (UG)
- Hospital Clínico San Carlos (ES)
- Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (ES)
- EsSALUD (PE)
- Centro Peruano de Estudios Sociales (PE)
- Molecular Oncology (United States) (US)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-01-09
- DOI
- https://doi.org/10.3389/fonc.2025.1719793
- Primary Topic
- Head and Neck Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00